Introduction
Despite the annual increase in the prevalence and incidence of heart failure (HF), 1 the underlying pathophysiology of this disease remains inadequately understood. Immune dysfunction is one of the key mechanisms underlying the occurrence and development of HF. 2 Initially identified in the serum of patients with dilated cardiomyopathy (DCM) in 1987, b 1 -adrenergic receptor autoantibodies (b 1 -AAs) can specifically bind to the second extracellular loop of the b 1 -adrenergic receptor (b 1 -AR) (b 1 -ECII) and has b 1 -AR agonist-like effects. 3, 4 The b 1 -AAs can also induce sustained activation of the b 1 -AR, 5 leading to HF. However, b-blockers cannot completely block damage to the myocardium induced by b 1 -AA 6 and improve the survival rate of patients with HF who are positive for b 1 -AAs-immunoglobulin G3. 7 Therefore, it is important to identify an effective mechanism to ameliorate myocardial injury induced by b 1 -AAs. Under physiological conditions, heart rate and contractility are regulated by cardiac b 1 -AR, whereas cardiac b 2 -ARs only play a minor role.
However, in situations of stress or HF, when large amounts of catecholamine are released, b 2 -AR activation may restrain the overactivation of b 1 -AR via the Gi pathway. 8 In addition, b 2 -AR activation plays a protective role in the injury of cardiomyocytes by inhibiting the apoptosis induced by b 1 -AR. 9 b 2 -AR autoantibodies (b 2 -AAs) have also been detected in patients with HF 10 and specifically bind to the second extracellular loop of the b 2 -AR (b 2 -ECII) to activate the receptor. 11 Therefore, a fundamental question that needs to be addressed is how the relationship between b 1 -AAs and b 2 -AAs is affected in relation to cardiac structure and function during HF when both autoantibodies coexist. Furthermore, it needs to be determined if b 2 -AAs can inhibit the damage induced by b 1 -AAs by activating the b 2 -AR. To address these questions, this study explored the impact of the imbalance between b 1 -AAs and b 2 -AAs on the cardiac structure both in patients with HF and in experimental settings, and its underlying mechanisms in vitro and in vivo.
Methods
This research study conformed to the Declaration of Helsinki. Patient confidentiality was preserved, and the anonymity of all patient data was safeguarded throughout the study. The study was approved by the local research ethics committee (Beijing Anzhen Hospital, Capital Medical University, Beijing, China). The animal studies complied with the recommendations in the Guide for the Care and Use of Laboratory Animals protocol and National Institutes of Health guidelines (Guide for the Care and Use of Laboratory Animals). This research study was approved by the Institutional Animal Care and Use Committee of Capital Medical University. The investigators understand the ethical principles by which the journal operates, and the study complied with the journal's animal ethics checklist (No. AEEI 2016-053). Before detecting cardiac function or collecting blood from the tip of the tail, mice were anaesthetized via a nasal mask with halothane (0.5 l/min) for about 30 s. At corresponding time points or the end of the experiment, the mice were euthanized with an intraperitoneal injection of 40 mg/kg sodium pentobarbital.
Patients with left systolic HF who suffered from coronary heart disease (CHD) (65.9%) or DCM (34.1%) were divided into New York Heart Association (NYHA) Classes I-II (n = 51) and Classes III-IV (n = 37) compared with healthy volunteers as controls (n = 41). The relationships were identified between cardiac function and b 1 -AAs, b 2 -AAs, and their positiveto-negative (P/N) ratio values. Neonatal rat cardiac myocytes (NRCMs) were used to detect beat frequency, cell death, necrosis, and apoptosis after stimulation with IgGs comprising b 1 -AAs and/or b 2 -AAs from the serum of patients with HF. HF models were induced by doxorubicin (DOX), isoprenaline (ISO), or b 1 -AAs/b 2 -AAs passive immunity using 10-week male Balb/c mice. Then cardiac function, and the level and ratio of b 1 -AAs and b 2 -AAs were detected. The detailed experimental procedures are described in the Supplementary material online.
Results

3.1
The ratio of b 1 -AAs and b 2 -AAs P/N values and its relationship to worsening HF The subjects were divided into three groups: healthy volunteers, patients with HF of Classes I-II, and HF Classes III-IV of NYHA. All patients had left systolic HF either induced by CHD (65.9%) or DCM (34.1%). Baseline and clinical characteristics of the study populations are shown in Table 1 . The serum optical density (OD) value of b 1 -AAs and b 2 -AAs of the different groups is shown in Table 1 ; if the P/N serum value was >2.1, the sample was considered positive. The results showed that the positive rate and OD values of b 1 -AAs or b 2 -AAs in HF patients were higher than those in healthy volunteers ( Figure 1A -C, positive patients are shown above the dotted line). However, the double positive rate of b 1 -AAs and b 2 -AAs was decreased with the increasing class of NYHA [11.8% (I-II) vs. 5.4% (III-IV); Figure 1A ]. Correlation analysis was used to explore the relationship between cardiac function and b 1 -AAs or b 2 -AAs. The results showed that a single b 1 -AAs or b 2 -AAs OD value had no correlation with left ventricular ejection fraction (LVEF) or left ventricular end-diastolic dimension (LVEDD) (see Supplementary material online, Figure S1A-D) . However, the b 1 -AAs/b 2 -AAs P/N ratio (b1/2-AAs P/N ratio) was negatively correlated with LVEF, but was positively correlated with LVEDD ( Figure 1D and E) (P/N value was used to standardize the OD value, all P/N values were > 0). Furthermore, the ratio was higher between healthy volunteers and HF patients ( Figure 1F) . However, the correlation between the ratio and cardiac function was weak (correlation coefficient was -0.2 between the ratio and LVEF, and 0.2 between the ratio and LVEDD), and was driven by several extreme cases.
3.2 b1/2-AAs P/N ratio was negatively correlated with cardiac function in DOXinduced and ISO-induced HF mice
Two HF mouse models were established to investigate the correlation between P/N ratio and cardiac function. In the first model, HF was induced by DOX injection (Figure 2A ). When compared with the saline group, the LVEF or LVEDD worsened, and the myocardium was damaged in the DOX-induced HF group (see Supplementary material online, Figure S2A-D) . Moreover, the OD value of b 1 -AAs increased, the b 2 -AAs remained at a high level, and their P/N ratio increased with HF progression in the DOX-induced HF group at 30 days ( Figure 2B-D) . The ratio of the b 1 -AAs and b 2 -AAs P/N value was negatively correlated with LVEF and positively correlated with LVEDD at all time points ( Figure 2E and F). When compared with patients with HF, the correlation between the ratio and cardiac function was stronger in DOX-induced HF mice (correlation coefficient was -0.526 between the ratio and LVEF, and 0.684 between the ratio and LVEDD). In the second mouse model, HF was induced by ISO injection (see Supplementary material online, Figure  SA-D) . Levels of both b 1 -AAs and b 2 -AAs were high halfway through the month, and then reduced in the end stage in ISO-induced HF mice (see Supplementary material online, Figure S3E and F). The other changes were similar to those in the DOX-induced HF mouse model including cardiac function deterioration, b1/2-AAs ratio increase, and a negative correlation with cardiac function (see Supplementary material online, Figure S3G -I) (correlation coefficient was -0.381 between the P/N ratio and LVEF, and 0.432 between the P/N ratio and LVEDD). Importantly, we found that a single b 1 -AAs or b 2 -AAs was not correlated, but the b1/ 2-AAs P/N ratio was negatively correlated with cardiac function in both patients with HF and the two HF mouse models. The high b1/2-AAs P/N ratio may have been due to the high level of b 1 -AAs and/or low level of b 2 -AAs. Because b 1 -AAs are highly expressed in HF, 10 these results suggest that b 2 -AAs may play a protective role in HF patients. Table S1 ). The total IgGs from the four patients were of high purity (see Supplementary material online, Figure  S4A beating were used (see Supplementary material online, Video). b 1/2 -ECII was 100% homologous between rats and humans, as determined using the NCBI blast database (see Supplementary material online, Figure S4D ); thus, IgGs from human serum were used to stimulate the rat cardiomyocytes. However, the peptides and receptor blockers had no effect on beat frequency, death, necrosis, and apoptosis of NRCMs (see Supplementary material online, Figure S6 ). Furthermore, the results showed that the P2 IgGs (b 1 þ/b 2 -) could increase the beat frequency of the cardiomyocytes and maintain it for >12 h ( Figure 4A) ; the effects could be neutralized by b 1 -ECII and inhibited by the b 1 -AR blocker metoprolol at 12 h ( Figure 4B ). When compared with P2, cardiomyocyte beat frequency and duration were less stimulated by P4 IgGs ( Figure 4A ), and this effect could be neutralized by b 2 -ECII and inhibited by the b 2 -AR blocker ICI118551 at 12 h ( Figure 4B ). ISO, as a nonselective agonist of b-AR, had a transient increase in beat frequency similar to the effect of P4. However, when b 2 -AR was blocked, ISO induced a sustained increase in beat frequency, similar to the effect of b 1 -AAs single-positive IgGs (P2) 5 (see Supplementary material online, Figure   S7A ). After blocking activation of b 2 -AR induced by ISO, the increased beat frequency was maintained for a longer duration than P2 12 (see Supplementary material online, Figure S7B ). The increase in beat frequency induced by P4 (b 1 þ/b 2 þ), rather than by P3 (b 1 -/b 2 þ), could also be almost completely inhibited by metoprolol at 3 h (see Supplementary material online, Figure S7B ). These results revealed that b 1 -AAs, rather than b 2 -AAs, induced the increase in beat frequency of NRCMs. To determine whether Gi or Figure S8A and B). Figure S10D and E). These results suggested that b 1 -AAs played a role in DOX-induced deteriorating cardiac function. 13 Passive immunity was also used to increase serum b 2 -AAs levels, and b 2 -ECII was injected into the tail vein to neutralize endogenous b 2 -AAs ( Figure 6A ). The passive immunity or neutralization of b 2 -AAs was successful ( Figure 6B ). The b 1 -AAs and b1/2-AAs P/N ratio decreased with increasing levels of b 2 -AAs ( Figure 6C and D) . When compared with the untreated group, b 2 -AAs could partly improve LVEF and LVEDD ( Figure 6E -G) as well as myocardial structural injury and myocardial apoptosis induced by DOX ( Figure 6H and I) . Furthermore, in the process of HF, the increase in b 2 -AAs levels via passive immunity or decrease in Figure  S11 ). These data suggested that b 2 -AAs could alleviate cardiac dysfunction and structural injury induced by b 1 -AAs in vivo.
Discussion
Our findings demonstrated that an imbalance between b 1 -AAs and b 2 -AAs exists in patients with HF and is likely a part of HF pathogenesis. The higher b1/2-AAs P/N ratio was related to a worse cardiac function in both patients and mice with HF. b 2 -AAs antagonized the damaging effects imposed by b 1 -AAs both in vitro and in vivo. A working model is illustrated in Figure 7 . Molecular homologies between cardiomyocyte surface proteins and microbial proteins are proposed as one possible mechanism underlying the cross-reaction of AAs directed against cardiac membrane receptors.
14 Another, probable and more relevant mechanism leading to the formation of endogenous heart-directed AAs may be primary inflammation or cardiac injury followed by sudden (or chronic) release of a 'critical amount' of potential self-antigens from the myocyte surface or cytoplasm previously thought to be hidden from our immune system.
14 Exposure of such antigens to the immune system may induce a host-directed autoimmune response, resulting in perpetuation of immune-mediated cardiac damage involving autoreactive T, B cells, or co-activation of both the innate and adaptive immune systems. 14 In our research study, both b 1 -AAs and b 2 -AAs could be induced in three HF models ( Figure 2 , see Supplementary material online, Figures S2 and S9) . However, the direct evidence is still needed to confirm the existence of mechanism to generate of AAs induced by inflammatory response in future research. The levels of b 1 -AAs in severe HF have been a debate up to date, as some studies have revealed that levels are high, 15 whereas others have suggested they are low. 16 These differences can be attributed to the different detection methods. 17 Our findings showed a higher level of b 1 -AAs in NYHA I-II than in III-IV ( Figure 1B) , possibly due to downregulation of b 1 -AR in severe HF. 18 Presumably, when b 1 -AR expression is decreased, exposure of abnormal antigen is reduced accordingly, thus leading to decreased production of AAs. 19 At the same time, Figure S1 ), similar to the results of previous studies. 22 The Figure 4D ). Although the activation of b 2 -AR/Gi can inhibit cardiomyocyte apoptosis induced by b 1 -AR, 27 it can also inhibit the activity of adenylyl cyclase leading to a decrease of cAMP and calcium. This effect can inhibit the shrinkage of cardiomyocytes and be ultimately detrimental for cardiac function in HF. Thus, b 2 -AAs activate the b 2 -AR/Gi pathway and exhibit a 'bidirectional' effect of cardiac function in HF. Thus, it appears that the 'bidirectional' effect of b 1 -AAs and b 2 -AAs causes the lack of relationship to cardiac function in HF. Further studies showed that the b1/2-AAs P/N ratio was negatively related to cardiac function in patients with HF ( Figure 1D and E). However, the correlation was weak and influenced by several extreme values, in accordance with previous studies. 25 b 1 -AAs levels in different patients with HF had different effects on cardiomyocyte function; some could significantly activate b 1 -AR, whereas others did not. 25 Individual differences of b 1 -AAs levels in patients with HF might be a reason that extreme values occurred and a weak correlation was observed due to different IgGs subtypes 7 or affinity to b 1 -ECII. 28 Two HF models induced by ISO or DOX were established to examine determine if a correlation existed. The two HF models revealed that the ratio was negatively correlated to cardiac function, the correlation coefficient was larger, and the distribution of data was more concentrated (Figure 2 , see Supplementary material online, Figure S2 ). Thus, the integrated effects of b 1 -AAs and b 2 -AAs affect the cardiac function of patients with HF. We did not find that the ratio of b 1 -AAs and the three AAs (b 3 -AAs, a 1 -AAs, and AT1-AAs) were related to cardiac function in these patients with HF (see Supplementary material online, Table S2 ). This suggested that the b1/2-AAs P/N ratio might be negatively related to cardiac function in specific HF cases. Figure S10 ). Upon injection of b 2 -AAs, the production of b 1 -AAs was decreased, the P/N ratio was significantly decreased, and the cardiac function and myocardial damage was improved. However, after injection of b 2 -ECII to neutralize the endogenous b 2 -AAs, the production of b 1 -AAs was increased, the P/N ratio significantly increased, and the cardiac function deteriorated and myocardial damage was severe ( Figure 6 ). Thus, by increasing of b 2 -AAs to reduce b1/2-AAs P/N ratio, cardiac function can be improved and myocardial damage can be inhibited. Since it was related to cardiac function in HF, the P/N ratio might be more meaningful than individual b 1 -AAs or b 2 -AAs levels for assessing cardiac function in HF.
Conclusions
In summary, we observed that the increased ratio of b 1 -AAs/b 2 -AAs was associated with worsening HF in patients. Moreover, b 2 -AAs from patients with HF was capable of suppressing the hypershrinking, necrosis, and apoptosis induced by b 1 -AAs from HF patients in NRCMs. Finally, b 2 -AAs was capable of alleviating myocardial damage and heart dysfunction induced by DOX in mice. The imbalance of b 1 -AAs and b 2 -AAs in patients with HF is a meaningful mechanism to progression of HF, and the increasing ratio of b1/2-AAs P/N might be a good clinical indicator of the deterioration state of cardiac function in patients with HF. 
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